SEATTLE, Oct. 20, 2020 /PRNewswire/
-- Arzeda, the Protein Design Company™, today announced
that the company has entered into a joint development agreement
with Amyris that leverages the complementary nature of the two
companies' technology platforms to accelerate the development and
commercialization of high value ingredients. This marks the second
joint project between the parties. Amyris and Arzeda collaborated
successfully on a Defense Advanced Research Projects Agency (DARPA)
Technology Investment Agreement (TIA) during the period of 2015 –
2019.
The objective of this Development Collaboration Agreement is for
Arzeda to design and develop novel enzymes for Amyris with unique
functionalities, which Amyris will incorporate into their
fermentation process to facilitate production of the target high
value ingredients. Funding of the project is milestone-based, with
Arzeda receiving an additional payment contingent on early success
as well as a value-share on product commercialization. Enzymes
being designed and developed by Arzeda for this project are not
found in nature and thus represent the power of the computational
platform to build enzymes with unique functionality without a
natural starting point. Amyris and Arzeda expect to have
fermentation strains containing enzymes designed by Arzeda
developed during 2021.
"We are very excited to again work with Amyris on bringing new
products to market by combining protein design and strain
engineering," said Alexandre
Zanghellini, Arzeda CEO. "Amyris is a pioneer of synthetic
biology, and our previous collaboration gave us tremendous respect
for their technical competency and professionalism. We witnessed
how Amyris' technology platform can dramatically accelerate the
development of products that incorporate Arzeda's designer enzymes
and proteins, and we are looking forward to this new commercial
partnership."
Sunil Chandran, Senior Vice
President R&D for Amyris, added, "We saw firsthand in our
previous work with Arzeda the power of combining physics-based
computational protein design, machine learning and rapid
experimental testing to access new enzyme functionality. We look
forward to deploying their unique technology platform and expertise
to further accelerate Amyris' product development."
About Arzeda
Since 2008 Arzeda has been harnessing
the power of computational protein design to create and manufacture
proteins that enhance our lives and protect our planet. In
partnership with Fortune 500 companies and industrial leaders, we
develop healthy and sustainable products with a clear path to
access the food ingredients industry globally. Arzeda's proprietary
protein design platform combines physics-based computational
protein design, machine learning and lab automation to expand the
reach of biotechnology beyond the solutions that nature
evolved. For more information, please visit
www.arzeda.com.
About Amyris
Amyris (Nasdaq: AMRS) is a science
and technology leader in the research, development and production
of sustainable ingredients for the Clean Health & Beauty and
Flavors & Fragrances markets. Amyris uses an impressive array
of exclusive technologies, including state-of-the-art machine
learning, robotics and artificial intelligence. Our ingredients are
included in over 3,000 products from the world's top brands,
reaching more than 200 million consumers. Amyris is proud to own
three consumer brands - all built around its No Compromise® promise
of clean ingredients: Biossance™ clean beauty skincare, Pipette™
clean baby skincare and Purecane™, a zero-calorie sweetener
naturally derived from sugarcane. For more information, please
visit www.amyris.com.
Media contact:
Atalanta
Rafferty. RF|Binder
Atalanta.rafferty@rfbinder.com
212-994-7511
View original content to download
multimedia:http://www.prnewswire.com/news-releases/amyris-and-arzeda-enter-into-development-collaboration-agreement-301155204.html
SOURCE Arzeda